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Antibodies to laminin in preeclampsia. Laminin is a large basement
membrane glycoprotein localized in the trophoblast, glomerular base-
ment membrane and in the mesangial matrix of human glomeruli. It
promotes the attachment of epithelial cells to basement membrane
collagen. We have found that 14 sera from 52 patients with severe
preeclampsia or eclampsia contain lgG and 1gM antibodies which react
with placental and kidney basement membranes. These antibodies were
specific for laminin and did not react with other basement membrane
proteins. They were able to fix complement. They have been demon-
strated by radial immunodill'usion, radioimmunoassay and immunollu-
orescence blocking studies. In primary cultures they were shown to
impair the attachment of trophoblast cells to basement membrane
collagen. High levels of circulating immune complexes were detected
only in sera from preeclamptic patients with circulating antibodies to
laminin. The auto-antibodies to laminin could play a major role in the
pathogenesis of severe preeclampsia by impairing the attachment of
trophoblast cells to placental basement membranes and by lixation to
the glomcrular basement membranes and mcsangial matrix.
Preeclampsia is characterized by the onset of hypertension,
proteinuria and edema after the 20th week of gestation in
previously normotensive women [11. Despite extensive inves-
tigation, the etiology of preeclampsia is unknown, Its incidence
is closely linked to increased placental trophoblast mass such as
seen in twin pregnancies, diabetes, Rhesus isoimmunization
and hydatidiform trophoblastic disease [2].
Histopathologic and immunopathologic studies at autopsy
have demonstrated the presence of thrombi in small arteries of
patients with preeclampsia [3] as well as focal accumulation of
fibrin in glomeruli, liver sinusoids and uteroplacental arteries
[4—71. These findings indicate that local or disseminated activa-
tion of the coagulation system may play an important role in the
pathogenesis of the disease. A considerable increase in shed-
ding of trophoblast cells from the placenta into the maternal
circulation could ultimately be responsible for these docu-
mented clotting abnormalities [8—13].
The mechanisms responsible for the extensive degeneration
and shedding of syncytial trophoblast cells during preeclampsia
have not been studied, These cells are normally anchored to the
trophoblast basement membrane (BM) which contains several
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well defined BM glycoproteins, including type IV collagen,
entactin, laminin and a heparan sulfate rich proteoglycan
[14—16]. Laminin is an ubiquitous BM glycoprotein which
promotes the in vitro adhesion of epithelial, endothelial, or
muscle cells to UM collagen (17]. Laminin probably also
mediates the in vivo attachment of cells to their underlying BM
by specific interaction with a cell surface binding protein and
BM collagen [18—20]. The effect of anti-laminin antibodies on
cell—attachment to BM remains unknown in vivo.
In the present work, we have tested the following hypothesis:
some women became immunized against laminin antigens dur-
ing severe preeclampsia or eclampsia; these anti-laminin anti-
bodies might bind to the trophoblast BM, impairing the anchor-
age of syncytial cells to their supportive BM, thus allowing their
increased shedding into the maternal circulation.
Methods
Patients
Sera from 27 eclamptic, 45 preeclamptie patients (20 mild and
25 severe forms) and 42 normal pregnant women of the same
gestational age (30 to 38 weeks) were used. All were
primigravid. Mild or severe preeclampsia was defined according
to the criteria of the American College of Obstetricians and
Gynecologists [1, 21], and of the American Committee on
Maternal Welfare [211. Preeclampsia was classified as mild if
one of the following signs or symptoms was found: a) blood
pressure of at least 160 mmHg systolic or 110 mmHg diastolic
on two occasions at least six hr apart; b) proteinuria of at least
5 g/24 hr; c) oliguria (urinary volume of less than 400 mliter/24
hr); d) visual or cerebral disturbances; e) pulmonary edema or
cyanosis. The presence of any one or more of these signs
marked the preeclampsia as severe. All patients with mild
precclampsia had significant proteinuria (>0.5 g124 hr). The
absence of diabetes, Rhesus isoimmunization, and lupus
erythematosus or immune glomerulonephritis was verified by
appropriate tests.
ImmunQfluorescence
Sent were tested for the presence of anti-BM antibodies by
indirect immunofluorescence using human or mouse placenta,
kidney, skin or the EHS sarcoma (a murinc tumor producing a
matrix of BM) as substrates [22, 23]. Non-specific immunoglob-
ulins present in normal placenta were extracted prior to im-
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munofluorescence studies by short term cultures, as described
previously [24]. In some studies, the same sections were first
incubated with the human sera or with the anti-laminin antibod-
ies (50 jsglmliter in phosphate buffered saline—PBS) purified by
affinity chromatography from these sera [23], and thereafter
with rabbit anti-mouse laminin antibodies (50 sWmliter). After
extensive washing with PBS, the distribution of human or rabbit
antibodies was revealed by a further incubation of the tissue
section with rhodamin—conjugated goat anti-human IgG and
with fluorescein—conjugated goat anti-rabbit IgG (Cappel, Penn-
sylvania, USA). These antibodies were rendered specific for
human or rabbit IgG by cross—immunoabsorption [22]. In other
studies, tissue sections were pretreated for two hours at 37°
with chondroitinase ABC (50 U/mliter) (Miles Lab., Elkhart,
Indiana, USA), testicular hyaluronidase (40 mg/mliter in PBS)
(type IV, Sigma, St. Louis, Missouri, USA) or bacterial colla-
genase (50 U/mliter) (Lynbrook form III, Advances
Biofactures, USA) in order to unmask antigens before the
incubation with the various anti-sera as described above. Im-
munofluorescence blocking studies were performed by a prior
incubation of sera (or affinity purified antibodies) in the pres-
ence of type IV or V collagens, laminin, fibronectin or bovine
serum albumin at a concentration of 100 /.Lglmliter for one hour
at 37° and overnight at 4°. The class of antibody bound to the
tissue sections was determined by using fluorescein—conjugated
goat anti-human IgG or 1gM (Cappell Laboratories, Cochran-
ville, Pennsylvania, USA). The ability of these antibodies to
activate the complement cascade was tested by an in vitro
immunofluorescence complement binding technique. The pres-
ence of C3 deposits was demonstrated after sequential incuba-
tions of the tissue sections with the patients' sera, with fresh
normal human serum (1:10 dilution in PBS as a source of
complement) and with fluorescein—conjugated rabbit anti-
human C3 antibody (Cappell) [25].
Double immunodiffusion. Double immunodiffusion according
to Ouchterlony was performed at 4° in 1% agarose gels as
previously described [22].
Antibody purification
Anti-laminin antibody was purified by affinity chromatogra-
phy of 20 mliter of "positive" sera on a Sepharose-4B-laminin
column [23]. After removal of the unbound material by exten-
sive washing with PBS, bound antibody was eluted with 0.5 M
NaC1, 0.5 M acetic—acid—pH 3. Fractions containing protein
were adjusted to pH 7.4, dialyzed against PBS, and concen-
trated to 50 sgImliter [22].
Elution of immuno globulins from placenta
Placental villi from five patients with eclampsia, five with
severe preeclampsia and five with normal pregnancy were
homogenized using an Ultra—Turrax blender (5 g tissue/20
mliter PBS). Soluble proteins were discarded after repeated
extraction of the homogenate with PBS. The insoluble material
was then extracted (three times for two hr at 4° with 0.2 M
citrate buffer—pH 2.5) [26]. Pooled supernatants of the extracts
were adjusted to neutral pH, dialyzed against PBS and concen-
trated 100 x by filtration on a UM 10 Amicon filter (Amicon,
Lexington, Massachusetts, USA). The protein concentration of
placental eluates was measured by the method of Lowry et al
[27]. Eluates were also analyzed by immunoelectrophoresis
using an antiserum directed against whole human serum (Behr-
ing, Hoechst, Belgium).
Immunological Assays
Antibody to laminin in human serum was detected by precip-
itation of ['251]-laminin by a double antibody precipitation
method [22], by immunoprecipitation of the immune complexes
with polyethyleneglycol (PEG) [28], by a solid phase radio-
immunoassay (RIA) using ['251]-protein A [29], and by an
automated latex immunoassay [30]. Murine laminin (10 ng)
purified from the EHS tumor was labelled with 125J by the
method of McConahey and Dixon [311. Free iodine was sepa-
rated from protein bound iodine by chromatography on a Biogel
P60 column (60 x 0.5 cm) followed by dialysis against borate
buffer (ionic strength 0. 1—pH 8.3 containing 0.04% Tween 20)
[28]. Binding of the labelled antigen to serial dilutions of human
serum or affinity purified antibody was measured by precipita-
tion of the immune complexes with an equal volume of a
solution containing 20% PEG [32, 331, or by double antibody
immunoprecipitation [22]. Addition of 0.5 mliter of 20% PEG
solution to 0.5 mliter of normal human serum diluted 40 x with
the borate—Tween buffer precipitated less than 5% of the
'251-laminin. In the same conditions, 1 jsg of rabbit antibody to
laminin precipitated 70 to 90% of total radioactivity. The
percentage of '251-laminin precipitated by the 20% PEG solution
in the sera from 42 normal pregnant women (at 1:40 dilution)
was 0.3 3% (mean SD). This percentage was 0.4 1%
(mean SD) when the second antibody technique was used. A
significant laminin binding capacity was considered to occur in
serum of patients only when at least 10% of the '251-Iaminin was
precipitated with PEG or with the second antibody.
Binding of antibody to laminin was also measured by solid
phase RIA, using laminin coated plates. Polyvinyl chloride
plates (PVC) (Cooke Lab., USA) were coated with laminin by
incubation for two hours at 37° (100 piiter/well of 5 g/mliter
laminin in PBS). After washing, residual binding sites were
blocked by incubation with 10% fetal calf serum (FCS) (100
piiter/well diluted in PBS-Tween containing 10% FCS). The
wells were then washed three times with PBS-Tween and
incubated at 37° for one hour in the presence of ['251]-protein A
(50 diter/well of 0.25 sgImliter). Unbound material was re-
moved by washing three times with PBS-Tween. Bound radio-
activity was measured by counting the cut out wells in a gamma
counter (LKB rack gamma II). At least five sera from normal
pregnant women were included as controls on each plate. At all
dilutions of sera from 30 normal non-pregnant women or 42
normal pregnant women, less than 0.2 0.1% of the [125I]
protein A was bound to laminin—coated wells, while affinity
purified rabbit anti-laminin antibody (0.6 tg/mliter) showed
binding of 65 to 70%. Significant binding to laminin was
considered to occur only when more than 1% of total radioac-
tivity bound to the wells.
In inhibition studies, human sera (1:40 dilution in PBS-Tween
containing 10% FCS) were incubated overnight at 4° in the
presence of various antigens (laminin, type IV collagen,
heparan—sulfate containing proteoglycan or bovine serum albu-
min) at a concentration of 50 g/mliter). After centrifugation for
30 mm at 15,000 rpm, supernatants were incubated in triplicate
on laminin—coated plates as described above. Percentage inhi-
bition was calculated by comparison of bound radioactivity in
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wells incubated with human sera preincubated without addition
of antigen.
Finally, the presence of antibodies to laminin in sera was
tested by an automated latex immunoassay [30]. Serially diluted
sera (in glycine buffered saline (GBS)—0.1 M glycine, 0.17 M
NaCI, 0.0076 M NaN3 adjusted to pH 9 with NaOH) were
incubated at 42° for 25 mm with calibrated (0.8 m in diameter)
latex particles on which laminin was adsorbed (12 g lamininl5
mg latex particle). PEG (4%, final concentration) was added to
the incubation medium. The agglutination was measured by
counting the remaining unagglutinated latex particles with a cell
counter as described in details by one of us [301. Normal human
sera at 1:3 dilution agglutinated 5% of the latex particles. When
diluted 24—fold these sera agglutinated less than 1% of the latex
particles. The presence of anti-laminin antibodies was investi-
gated in a large series of samples at this dilution. Human serum
diluted 1:24 with GBS was considered to contain antibody to
laminin when at least 10% of the laminin—coated latex particles
were agglutinated. An excellent correlation was found between
anti-laminin antibody titers determined by the three immuno-
logical techniques. Linear regression coefficients between anti-
body titers determined were respectively: ['251]-protein
A—double antibody precipitation method : r2 = 0.88, (P < 0.01);
double antibody precipitation—latex imrnunoassay : r2 = 0.96,
(P < 0.001); ['251]-protein A—latex immunoassay : r2 = 0.95, (P
<0.001).
Complement and jmmune complex assays
The serum levels of C3 and C4 were routinely measured by
laser nephelometry (Travenol, Hyland Lab., Costa Mesa, Cal-
ifornia, USA). Conglutinin test was performed according to
Casali et al [34j. Circulating immune complexes were also
detected by the classical liquid phase ['2511-CIq binding assay
[35).
Adhesion of human irophoblast cells
Trophoblast cells were isolated by mild trypsin treatment of
first trimester placental villi according to Thiede [36]. Cells
were applied to a Ficoll—Hypaque gradient (Pharmacia, Upp-
sala, Sweden), centrifuged at 1200 rpm for 45 mm and pelleted
cells discarded. Cells remaining at the interphase were plated in
Linbro culture dishes (Flow Lab., USA) with TC 199 medium
containing 10% FCS. Trophoblast identity of these isolated
cells was established by thc following criteria: a) their morphol-
ogy by light and electron microscopy; b) their ability to produce
placental polypeptide hormones (4.5 1 g human placental
lactogen, HPL/l06 cells/day and 2 0,3 IU human chorionic
gonadotrophin, I-ICG/l 06 cells/day); C) their immunostaining
after four days in culture of over 90% of the cells by an
anti-HPL antibody using immunofluorescence and/or immuno-
peroxidase technique. In these experiments, human dermal
fibroblasts (sixth passage) were used as control cells.
Adhesion studies were performed according to previously
described techniques [17, 37, 38]. Cells were plated on plastic or
on type IV collagen (1 mliter/welI of 10 g/mliter in 0.1 M acetic
acid) prepared either from the EHS tumor [39] or from human
placenta [40]. Acetic acid was removed by evaporation for 48
hours under ultraviolet irradiation. For the cell—attachment
assay, laminin (5 .tg/mliter) or antibody to laminin (5 rg/mliter)
plus cells (2 x l0) were added to the culture medium (0.9
Fig. 1. Normal human skin. Double immunofluorescent localization of
human BM using human antibody to laminin purified from serum of
eclamptic patients, A, or rabbit antibody purified from antiserum of
rabbits immunized against mouse laminin, B (x 64).
mliter of TC 199 medium containing 10% FCS). After six hours
incubation, unbound cells were removed by washing with fresh
culture medium. Attached cells were trypsinized and counted in
a Thoma cell and an electronic cell counter (Coulter Counter).
At least six assays were performed for each experimental
condition.
Results
linmunofluorescence studies
No antibody binding to human or animal tissues was detect-
able by immunofluorescence in the serum from 30 non-pregnant
women, 42 normal pregnant women and 20 patients with mild
preeclampsia. On the contrary, the sera from five of 25 patients
with severe preeclampsia and nine of 27 patients with eclampsia
contained antibodies able to bind to human BM in tissues such
as placenta, kidney, skin or muscle as demonstrated by im-
munofluorcseence microscopy. Their titers ranged from 1/4 to
1/32, Their tissue distribution therefore closely resembled that
of rabbit antibody against the BM protein laminin [221. Prior
incubation of human sera with laminin completely blocked the
binding of these antibodies to the tissue substrates. However,
prior incubation with other highly purified connective tissue
proteins (including type IV or V collagens, fibronectin, entactin
or heparan sulfate proteoglycan) did not strongly modify the
substrate binding.
The tissue reactive antibodies could be isolated from the sera
of preeclamptic or of eclamptic patients by affinity chromatog-
raphy on a laminin—Sepharose column. These antibodies bind to
BM of human tissues (Fig. I). The staining pattern was identical
to that obtained with the corresponding sera. The pattern of
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staining of these affinity—purified anti-laminin human antibodies
was then compared to that of rabbit antibodies to laminin by
double immunolocalization. Both types of antibodies displayed
identical distributions on dermo-epidermal BM, capillary BM
and smooth muscle BM (Fig. 1A, B). Both human and rabbit
antibodies also bound to the matrix of the EHS sarcoma in an
identical pattern (not shown). In kidney, antibodies purified
from the sera of preeclamptic or eclamptic women reacted with
the mesangial matrix and the glomerular BM as well as with the
peritubular capillary BM. Only a faint reaction was detected in
Bowman's capsule and tubular BM, whereas rabbit anti-laminin
antibodies strongly stained all kidney BM. When injected into
mice [41], human antibodies strongly bound to the mesangial
matrix and glomerular BM (Fig. 2). These antibodies were
shown to be of 1gM and IgG classes and able to bind comple-
ment. Prior treatment of tissue sections with hyaluronidase,
bacterial collagenase or chondroitinase ABC did not strongly
modify the distribution nor staining intensity.
Double immunodjffusion
The sera from 30 normal non-pregnant, 42 normal pregnant or
20 mild preeclamptic women did not react with laminin in
Ouchterlony gels. The sera from two of 27 eclamptic women
and three of 25 preeclamptic patients contained antibodies able
to precipitate laminin in this test. These same sera contained by
immunofluorescence antibodies binding to BM. Affinity purified
antibody to laminin from these same sera also precipitated
laminin. An identity line was observed between the laminin
precipitated by human and rabbit anti-laminin antibodies.
Immunological studies
Sera from 30 normotensive non-pregnant women, 42 normal
primigravid and 20 patients with mild preeclampsia did not
contain anti-laminin IgG, detectable by ['251]-protein A reacting
with antibodies bound to laminin coated wells. On the contrary,
anti-laminin IgG was found in serially diluted sera of patients
with severe preeclampsia (Fig. 3A). Anti-laminin antibody titers
ranged from 80 to 320. The presence of such antibodies was
then evaluated in a large series of patients using a 25—fold
dilution of serum in order to further decrease the percentage of
non-specific binding. Sera from nine of 27 eclamptic women and
five of 25 patients with severe preeclampsia exhibited signifi-
3 6 12 24 48 96 Dilution
Fig. 3. Detection of anti-laminin antibody by using ['251J-protein A, A,
by radioimmunoassay, B, or by agglutination of latex particles coated
with laminin, C. A. Titration curve of two human sera (—•) from
preeclamptic patients or of human antibody to laminin (40 g/mliter)
purified from sera of eclamptic women (A—A). The right panel indi-
cates the percentage of binding of ['251]-protein A to laminin—coated
wells after incubation in the presence of diluted serum (1:25) from
preeclamptic (•) or eclamptic (A) women. The dashed zone represents
the maximal non-specific binding. B. Titration curve of purified rabbit
antibody to laminin by radioimmunoassay using either PEG or a double
antibody technique in order to precipitate the immune complexes. The
right panel shows the percentage of ['251]-laminin precipitated by
diluted serum (1:40). C. Titration curve of six sera from preeclamptic
patients by agglutination of latex particles coated with laminin. The
right panel shows the percentage of agglutinated particles by diluted
serum (1:24).
cant titers of anti-laminin antibody (Fig. 3A). Prior incubation
of these sera or of affinity purified human antibodies to laminin
Fig. 2. Distribution in mouse kidney of human antibody to laminin.
Hundred micrograms of purified antibody to laminin were injected
intravenously in a normal mouse. In vivo bound human immunoglob-
ulin G was detected by immunolluorescence 30 mm later. Tm-
munofluorescent deposits are localized to the glomerular BM (x 64).
10
5
10 20 40 80 160 Dilution
80
40
PEG (2O%)
Double antibody
— I S I S
4 4.102 4.10
p.g lgG/mliter
A
10
5
B
80
40
C
1 QO
50
C
0
.0
C
a
0
0.
C
C
Ea
a
a
a
0.
aa
C)ta0.
xa
a
a
aC
C,C,a
0
A
A
A
••A
A.
A
AA
•A
.A •
•A
A
A
A
A
A
100
1054 Foidart et a!
Table 1. Complement and immune complexes in preeclamptic patients with or without circulating antibody to laminin
Patients
Normal pregnant
women
Preeclamptic—eclamptic + antibodies
patients against laminin
— antibodies
against laminin
* Mg/l00 muter (mean SD).
with this antigen completely abolished the binding. Incubation
with type IV or V collagen, fibronectin or bovine albumin did
not prevent subsequent binding to laminin coated wells.
Figure 3B shows the binding of various concentrations of
rabbit anti-laminin antibody to 10 ng of '251-laminin. In the
presence of the sera (diluted 40 times) from 20 patients with
mild preeclampsia, 42 normal primigravid and 30 normal non-
pregnant women, the 20% PEG solution precipitated less than
10% of added '251-laminin. On the contrary. sera from five of 25
severe preeclamptic women and nine of 27 eclamptic patients
contained significant titers of anti-laminin antibodies (Fig. 3B).
Prior incubation of the patient's sera with laminin inhibited
antibody binding. In contrast, type IV and V collagens, fibro-
nectin and bovine albumin did not inhibit antibody binding to
'251-laminin. Comparable results were obtained using the dou-
ble antibody immunoprecipitation method.
The presence of antibody to laminin in sera from
preeclamptic—eclamptic patients was further confirmed by their
ability to agglutinate latex particles coated with laminin (Fig.
3C). Among patients with circulating anti-laminin antibodies, a
good correlation was observed between the titers defined by the
three immunological methods. Higher titers of anti-laminin
antibodies were usually found in eclamptic patients as com-
pared with those with preeclampsia (Fig. 3).
Complement and immune complexes
Serum levels of C3 and C4 were unchanged in preeclamptic—
eclamptic women in comparison with those with normal preg-
nant women of the same gestational age (Table 1). Patients with
circulating antibodies to laminin also exhibited normal serum
levels of C3 and C4. While the conglutinin test was negative in
all pregnancies examined, the liquid phase [1251J-Clq binding
assay demonstrated the presence of circulating immune corn-
plexes in the serum from eight of 14 preeclamptic—eclamptic
patients showing antibodies to laminin. The six other "posi-
tive" patients as well as the other preeclamptic or eclamptic
patients and the normal pregnant women exhibited normal
values of ['251]-Clq binding activity of their sera (Table 1).
Placental eluates, cord sera
Placental eluates from five eclamptic women (with circulating
antibodies to laminin) contained IgG and 1gM as demonstrated
by immunoelectrophoresis. Part of these antibodies reacted
with laminin by immunofluorescence studies and solid or liquid
phase RIA (Table 2). Placental eluates from five normal preg-
nant women and five preeclamptic patients (whose serum was
devoid of anti-laminin antibodies) did not contain detectable
amounts of antibody to laminin. Finally, anti-laminin antibody
was detected in only two cord sera from newborn babies whose
mother's sera exhibited anti-laminin antibody. These infant sera
immunoprecipitated 14% and 18% of the '251-laminin respec-
tively added to the liquid phase RIA and boundS and 10% of the
['251J-protein A in the solid phase RIA. Serum titers were
identical in maternal and fetal sera. Cord serum from the second
newborn child also showed significant Clq binding activity
(15.6%). Other cord sera from infants of preeclamptic women
immunized against laminin (N = 12)did not contain antibody to
laminin or immune complexes, Such antibodies and immune
complexes were also absent from cord sera of 42 normal
primigravid and 20 patients with mild preeclampsia.
Influence of human anti-laminin antibodies on trophohiast
cell attachment
Addition of exogenous laminin stimulated attachment in vitro
of human trophoblast cells but not fibroblasts to type IV
N
Complement*
C3 C4
[°51J—Clq
% binding activity
42 133±46 23±4 5.6±3
14 127 24 19 5 37.3 8
60 141 32 26 7 6,2 1.6
Patients
I
IF
32
Table 2. Anti-laminin antibody
Anti-laminin antibody titers in serum
-—-
['231]-protein PEG
A precipitation
in placental eluates of eclamptic patients
Anti-laminin antibody titers
-—-- —
Total protein
concentration
(mg/mI) IF
0.49 ND*
in placental eluates
—---—
lus1Jprotein
A
2.9
PEG
precipitation
249.9 87
2 32 9.2 80 0.47 undiluted 3.4 32
3 16 8.3 59 0.61 4 4.5 42
4 8 4.1 48 0.54 2 2.6 19
5
* ND: not
4 3.7 37
detectable
0.58 8 5.1 53
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Table 3. In vitro effect of human anti-laminin antibodies on human trophoblast cell plating efficiency
Percentage of cells attached to BM collagen
Trophoblast
Medium cells Fibroblasts
Alone 49±5 79±10
Containing soluble laminin (5 sgImliter) 71 7* 85 9
Containing human antibody to laminin (5 g/mliter) 35 8** 78 12
Containing non.specific human IgG (5 gImliter) 52 7 75 7
Plus laminin (5 .sWmliter) + human antibody to laminin (5 sglmliter) 44 8 83 8
* Significantly different from medium alone, P < 0.01, Student's t-test.
** P < 0.05.
collagen coated dishes (Table 3). Addition of human antibodies
to laminin inhibited the adhesion of human trophoblast cells to
type IV collagen and also abolished the stimulating effect of this
protein on the attachment of trophoblast cells. Normal human
IgG did not influence the binding of these cells to type IV
collagen. Furthermore, human dermal fibroblast attachment to
type IV collagen was not modified by either laminin or anti-
laminin antibodies (Table 3).
Discussion
Nine from 27 eclamptic and five from 25 preeclamptic pa-
tients sera contained antibodies that reacted with BM. These
sera were found to contain moderate titers of antibodies to
laminin but not to other connective tissue components. The
identification of laminin as the tissue antigen was established by
several methods including immunoprecipitation, immunoabsorp-
tion, Ouchterlony immunodiffusion, agglutination, binding to
laminin coated wells, inhibition immunofluorescent staining,
and inhibition RIA in solid and liquid phase.
Reactivity of human anti-laminin antibodies was identical
with that of rabbit anti-laminin on BM. However, rabbit anti-
laminin antibodies reacted uniformly with all BM whereas
antibodies from preeclamptic patients showed a distribution
limited to most, but not all, BM. We have previously described
similar patterns of reactivity of antibodies to laminin in Chagas
disease [381. The heterogeneous rabbit antibodies are probably
directed against a variety of antigenic sites in laminin. Antibod-
ies arising in preeclampsia may recognize fewer and different
antigenic determinants in laminin. It is also possible that
interactions between laminin and other BM components such as
entactin, type IV collagen or heparan sulfate proteoglycan
might prevent binding of human antibodies to all BM. As might
be expected, the titers with human sera were considerably
lower than those of rabbit antisera. It is possible that human
anti-laminin antibodies bind only to those BM containing a
sufficient density of accessible laminin antigen.
It is not clear why patients with severe preeclampsia or
eclampsia develop antibodies to laminin. They were not de-
tected in sera from 30 non-pregnant or 42 normal pregnant
women. Their absence from mild cases suggests that gestational
hypertension is not an auto-immune disease secondary to the
onset of anti-laminin antibody. The anti-laminin antibodies in
preeclampsia may be the consequence rather than the cause of
the disease. Antibodies to trophoblast [42, 43]; to an amniotic
fluid glycoprotein [44]; to uncharacterized placental, renal or
hepatic antigens [45—47]; or to a placental carbohydrate [48]
have been previously described in serum from preeclamptic
patients. It is plausible that the development of such antibodies
is the consequence of placental lesions and leakage of placental
antigens into the maternal circulation.
We have previously described the occurrence of auto-antibod-
ies to laminin in patients with various diseases involving BM
such as Chagas disease [38], Goodpasture's syndrome as well
as other glomerulonephritides [33, 49]. The presence of anti-
bodies to laminin in serum is thus not restricted to nor specific
of preeclampsia—eclampsia.
Failure to observe antibodies to laminin in patients with mild
preeclampsia is rather puzzling. Certainly such antibodies
ought to be present at an early stage of the disease if they have
a pathogenic role. It is possible that the bulk of anti-laminin
antibody present in mild preeclampsia is bound to maternal
tissues and that this antibody circulates at levels below the
assay's detection limit. Diagnosis of mild or severe
preeclampsia in this study was based on clinical criteria alone.
Renal biopsy confirmation of the absence of underlying kidney
disease was not obtained. It is therefore possible that at least
part of the patients with mild gestational hypertension had
chronic renal disease or conversely that patients classified here
as severe preeclampsia—eclampsia have an underlying renal
condition [50]. Correlative biopsy data might help in further
delineating disease entity and pathogenic significance of anti-
laminin antibody.
They could, however, play an important pathogenic role and
contribute to the severity of lesions in placenta, kidney, liver
and uteroplacental arteries. 1gM, IgG and C3 deposits in the
walls of uteroplacental arteries as well as mesangio-parietal
accumulation of 1gM and IgG in glomeruli of patients with
preeclampsia have been previously documented in severe forms
of the disease [6, 7, 5 1—55]. At least part of this in vivo bound
immunoglobulin could include antibodies to laminin since this
protein is abundant in those histological structures. Placental
eluates from the five eclamptic patients examined contained in
vivo bound antibody to laminin. IgG, 1gM and C3 deposits have
been previously demonstrated by immunofluorescence in villi
of normal or preeclamptic women [24, 26]. The anti-laminin
antibodies described here were complement—fixing of 1gM and
IgG classes, and as such, could contribute in accelerating the
shedding and embolization of trophoblast cells [8—13]. Our
demonstration that anti-laminin antibody specifically inhibited
in vitro the binding of trophoblast cells to BM collagen further
supports the hypothesis that these antibodies could play an
important role in the in vivo detachment and embolization of
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these cells during preeclampsia. We have previously shown that
purified rabbit antibody to laminin administrated intravenously
to pregnant mice induced proteinuria as well as a high incidence
of abortion, retroplacental hematoma and fetal death [41, 56].
Binding of antibodies against laminin to placental BM could
also partly explain the increased degeneration of the syncytial
trophoblast [57J and the decreased laminin content of
preeclamptic villi [58]. It is thus tempting to speculate that
antibodies to laminin demonstrated here may play a significant
role in severe preeclampsia.
If antibodies to laminin were pathogenic in causing the
disease, or aggravating renal and placental lesions, one might
wonder why preeclampsia is usually a disease of the first
pregnancy only. Goodpasture syndrome, another renal disease,
closely related to the presence of circulating anti-BM antibody
[59], however, does not usually recur after renal transplantation
provided that surgery be performed after disappearance of the
circulating anti-BM antibody 160]. One might thus speculate
that the anti-laminin antibodies present in preeclampsia could,
like in the Goodpasture syndrome, play an important patho-
genic role hut not recur in subsequent pregnancies after disap-
pearance from serum.
The occurrence of circulating immune complexes during
preeclampsia is controversial because different methods have
yielded contradictory results. Masson, Delire and Cambiaso
[611 described high levels of immune complexes in blood of
normal pregnant women. Thomson el al [62], Stirrat, Redman
and Levinsky 1631 and Vazquez—Escobosa, Perez—Medina, and
Gomez—Estrada 1641 could only identify such complexes in
serum of preeclamptic women. Knox et at 1651 did not demon-
strate any circulating immune complexes in sera of normal or
preeclamptic pregnant women. The presence of such com-
plexes only in patients sera containing antibodies against
laminin suggests that some of these immune complexes could
contain laminin anti-laminin antibodies. Their pathogenic sig-
nificance in preeclampsia remains unknown.
Altogether this study indicates that patients with severe
preeclampsia or eclampsia may have circulating and in vivo
bound antibodies to laminin. Such antibodies may play an
important pathogenic role. Further clinical studies are required
to evaluate the possible prognostic significance and the clinical
importance of the antibodies demonstrated here.
Reprint requests to Dr. J. M. 1'oidart, I)eparunent of Obstetrics and
Gynecology, University of Liege, 81, bd de Ia Constitution, B-4020
Liege, Belgium
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